• Structural Basis of HCAR3 Agonist Selectivity in Lipid Metab

  2026-06-11

  Ye et al. (2025) present high-resolution cryo-EM structures of HCAR3 and HCAR2 receptors in complex with selective agonists, including (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid (Acifran). The study elucidates the molecular determinants of ligand recognition and selectivity, advancing the rational design of hypolipidemic agents and tools for dissecting lipid metabolism regulation.

• Foretinib (GSK1363089): Multikinase Inhibition in Cancer Mod

  2026-06-10

  Foretinib (GSK1363089) is a potent ATP-competitive multikinase inhibitor with nanomolar efficacy against Met, VEGFR2, and related kinases. It robustly suppresses tumor growth, cell motility, and metastasis in in vitro and in vivo cancer models. This article details mechanistic action, validated protocols, and common misconceptions for effective research use.

• Dissecting Drug Response Metrics in Cancer: Insights from In

  2026-06-10

  Schwartz (2022) critically redefines how anti-cancer drug responses are measured in vitro, emphasizing that relative and fractional viability capture distinct biological outcomes—growth inhibition and cell death, respectively. This has practical implications for interpreting the impact of ferroptosis inducers, such as RSL3, and for designing more informative cancer drug screens.

• Isoprenaline Hydrochloride in Cardiac and Heart-Brain Axis M

  2026-06-09

  Isoprenaline Hydrochloride (isoproterenol) is a non-selective β-adrenoceptor agonist widely used in cardiac arrhythmia and neurobehavioral research. Its robust physico-chemical profile supports reproducible modeling of sympathetic overactivation in both cell and animal systems. Recent evidence underscores its value in dissecting the mechanistic interplay between cardiac and brain function.

• Optimizing Cell Assays with MTT (3-(4,5-Dimethylthiazol-2-yl

  2026-06-09

  This article provides a scenario-driven, evidence-backed exploration of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) for reproducible cell viability, proliferation, and cytotoxicity assays. Focusing on SKU B7777, we address real laboratory challenges and highlight APExBIO's role in delivering reliable, high-purity MTT solutions for biomedical research.

• E-64 and Lysoptosis: Strategic Horizons in Cysteine Protease

  2026-06-08

  This thought-leadership article explores E-64’s mechanistic power as a benchmark L-trans-epoxysuccinyl peptide cysteine protease inhibitor, focusing on its pivotal role in dissecting the evolutionarily conserved lysoptosis pathway. By integrating biological insight, experimental protocols, competitive context, and translational impact, we deliver strategic guidance for researchers seeking to advance the frontier of regulated cell death studies.

• GI 254023X: Selective ADAM10 Inhibitor for Vascular Research

  2026-06-08

  GI 254023X empowers researchers to dissect ADAM10-driven pathways with nanomolar selectivity, enabling precise interrogation of vascular integrity, apoptosis, and cell signaling. Its workflow flexibility and robust potency make it a premier choice for advanced preclinical models and mechanistic studies.

• Leucomycin (Kitasamycin): Enabling Next-Gen Translational In

  2026-06-07

  Leucomycin (kitasamycin) stands at the intersection of mechanistic insight and translational innovation for antibacterial drug discovery. This article examines its structure-activity relationships, experimental evidence, and strategic guidance for translational researchers, highlighting advanced workflows and resistance studies. Drawing from foundational studies and recent workflow enhancements, we position Leucomycin as a cornerstone for next-generation translational inhibition investigations, with practical recommendations for robust assay development.

• Strategic Insights: Amyloid β-Peptide (1-42) for Translation

  2026-06-06

  This article offers scientific and strategic guidance for translational researchers using Amyloid β-Peptide (1-42) (Aβ42 peptide) in Alzheimer's disease research. It blends mechanistic insight, validated protocols, and competitive perspectives, emphasizing evidence-based advances in neurotoxicity assays, neuronal ion channel modulation, and microglial response. The piece contextualizes the value of high-purity Aβ42 reagents, such as those from APExBIO, while extending beyond standard product pages to integrate translational relevance and visionary outlook.

• Tamoxifen in Translational Research: Mechanisms and Strategy

  2026-06-05

  This article offers a strategic, evidence-driven guide for translational researchers leveraging tamoxifen—a selective estrogen receptor modulator—across oncology, developmental biology, and genetic engineering. By dissecting recent mechanistic findings and protocol nuances, we illuminate both the promise and pitfalls of tamoxifen, informed by pivotal studies and APExBIO’s high-purity product offering.

• Efficient Purification of Recombinant Annexin V for Biophysi

  2026-06-05

  Burger et al. introduce a rapid and effective protocol for purifying recombinant annexin V, crucial for advanced biophysical analyses such as crystallography and single-channel electrophysiology. The approach emphasizes gentle cell lysis and calcium-dependent affinity steps, ensuring high purity and functional integrity of annexin V.

• Potassium Iodide for Thyroid Protection & Advanced Assays

  2026-06-04

  Potassium Iodide (KI) is pivotal for thyroid hormone synthesis and radioprotection, but its true value emerges in advanced immunotherapy and nanotechnology-enabled research. This article bridges classic applications with cutting-edge workflows, offering stepwise protocols, troubleshooting strategies, and insights from the latest responsive drug delivery innovations.

• Resiniferatoxin (RTX): Enhancing TRPV1 Assays & Pain Models

  2026-06-04

  This article addresses practical laboratory challenges in cell viability, cytotoxicity, and pain pathway assays, focusing on reproducibility, sensitivity, and workflow optimization. Resiniferatoxin (RTX, SKU BA7012) is contextualized as a highly selective TRPV1 agonist with robust evidence for chemical inactivation of TRPV1 and sensory neuron desensitization. Candid, scenario-driven Q&A blocks guide researchers through experimental design, data interpretation, and product selection, referencing APExBIO’s RTX as a validated solution.

• Hexa His Tag Peptide: Optimizing 6X His Protein Purification

  2026-06-03

  The Hexa His tag peptide enables precise, antibody-free elution in 6X His fusion protein workflows, minimizing contamination and enhancing experimental reproducibility. See how this versatile tool streamlines immunoprecipitation and protein interaction analysis, with actionable troubleshooting and protocol insights for next-generation molecular biology.

• Resiniferatoxin: Targeted TRPV1 Silencing for Precision Anal

  2026-06-03

  Szallasi’s review distills decades of research on resiniferatoxin (RTX), highlighting its unique potency and selectivity for TRPV1-positive sensory neuron ablation. The article details RTX’s clinical and experimental roles as a precision agent for long-lasting analgesia, underscoring its translation from natural product to advanced pain management tool.

451 records 15/31 page Previous Next First page 上5页 1112131415 下5页 Last page